Two Cells Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 12

Two Cells General Information

Description

Developer of regenerative medicine intended to regenerate tissues and organs that cannot be regenerated naturally. The company's medicine uses mesenchymal stem cells which is a treatment method in which MSC is taken out, increased in number outside the body, and transplanted into the patient's body, enabling patients to select new treatment methods through the spread of regenerative medicine.

Contact Information

Website
www.twocells.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 11th floor Hiroshima Industrial Culture Center
  • 16-35 Hijiyamahonmachi, Minami-ku
  • Hiroshima, 732-0816
  • Japan
+81
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 11th floor Hiroshima Industrial Culture Center
  • 16-35 Hijiyamahonmachi, Minami-ku
  • Hiroshima, 732-0816
  • Japan
+81

Two Cells Timeline

2021202220232024
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Two Cells Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 26-Apr-2024 Completed Clinical Trials - Phase 3
5. Secondary Transaction - Private 01-Dec-2022 Completed Clinical Trials - Phase 3
4. Later Stage VC 26-Nov-2021 Completed Clinical Trials - Phase 3
3. Later Stage VC 20-Nov-2019 Completed Clinical Trials - Phase 3
2. Later Stage VC 06-Jul-2017 $5.92M $8.26M Completed Clinical Trials - Phase 3
1. Seed Round 31-May-2016 $2.34M $2.34M Completed Clinical Trials - Phase 3
To view Two Cells’s complete valuation and funding history, request access »

Two Cells Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
A Preferred
To view Two Cells’s complete cap table history, request access »

Two Cells Patents

  • 223

    Total Documents Applications and Grants

  • Total Patents Families

  • 132

    Granted

  • 25

    Pending

  • Expiring in next 12 mo

Two Cells Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024043961-A Intervertebral disc therapeutic agent Pending 20-Sep-2022
AU-2021337035-A1 Composition for treating central nervous system diseases, method for producing composition for treating central nervous system diseases, and method for producing therapeutic formulation for central nervous system diseases Pending 03-Sep-2020
EP-4209223-A1 Composition for treating central nervous system diseases, method for producing composition for treating central nervous system diseases, and method for producing therapeutic formulation for central nervous system diseases Pending 03-Sep-2020
US-20230302055-A1 Composition for treating central nervous system diseases, method for producing composition for treating central nervous system diseases, and method for producing therapeutic formulation for central nervous system diseases Pending 03-Sep-2020
JP-7444267-B2 Composition for treating central nervous system diseases, method for producing compositions for treating central nervous system diseases, and method for producing formulations for treating central nervous system diseases Active 03-Sep-2020 A61P21/00
To view Two Cells’s complete patent history, request access »

Two Cells Executive Team (13)

Name Title Board Seat
Masaya Matsumoto Chief Executive Officer & President
Aki Ohmori Inventor
Jin Shao Inventor
Ken Innami Inventor
Masato Takao Inventor
You’re viewing 5 of 13 executive team members. Get the full list »

Two Cells Board Members (1)

Name Representing Role Since
Koichiro Tsuji Two Cells Executive Chairman
To view Two Cells’s complete board members history, request access »

Two Cells Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
FFG Venture Business Partners Corporate Venture Capital Minority
Hiroshima Capital Partners Growth/Expansion Majority
Hiroshima Innovation Network PE/Buyout Minority
Hiroshima Venture Capital Venture Capital Minority
Iyogin Capital Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

Two Cells FAQs

  • When was Two Cells founded?

    Two Cells was founded in 2003.

  • Who is the CEO of Two Cells?

    Masaya Matsumoto is the CEO of Two Cells.

  • Where is Two Cells headquartered?

    Two Cells is headquartered in Hiroshima, Japan.

  • What industry is Two Cells in?

    Two Cells’s primary industry is Drug Discovery.

  • Is Two Cells a private or public company?

    Two Cells is a Private company.

  • What is Two Cells’s current revenue?

    The current revenue for Two Cells is .

  • How much funding has Two Cells raised over time?

    Two Cells has raised $43.6M.

  • Who are Two Cells’s investors?

    FFG Venture Business Partners, Hiroshima Capital Partners, Hiroshima Innovation Network, Hiroshima Venture Capital, and Iyogin Capital are 5 of 12 investors who have invested in Two Cells.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »